BMS-690514

BMS‑690514 is a pyrrolotriazine-based small molecule that acts as a potent and reversible oral inhibitor of multiple receptor tyrosine kinases. Specifically, it targets the epidermal growth factor receptor (EGFR/HER‑1), HER‑2 and HER‑4 receptors (members of the ERBB family), as well as vascular endothelial growth factor receptors VEGFR‑1 to VEGFR‑3. By inhibiting these pathways simultaneously, BMS‑690514 was designed to block tumor cell proliferation and angiogenesis in cancer. It was developed by Bristol Myers Squibb for use as an oral antineoplastic agent in cancers such as non-small cell lung cancer and breast cancer; however, clinical development for these indications has been discontinued after phase II trials.[7][8][5][6]

Other names

(3R,4R)-4-Amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol(3R,4R)-4-amino-1-{4-[3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin–5–yl}methyl)piperidin–3–ol